SCHEMBL19973027

SCHEMBL19973027

O=C1CC[C@@H](CON2C(=O)c3ccccc3C2=O)N1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.45
▸ PDK2 Q15119 3/20 0.44
▸ ALDH1A1 P00352 5/20 0.43
▸ CYP1A2 P05177 3/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ OPRM1 P35372 1/20 0.43
▸ DDB1 Q16531 1/20 0.43
▸ CRBN Q96SW2 1/20 0.43
▸ IKZF3 Q9UKT9 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ CYP2C9 P11712 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ GABRA1 P14867 1/20 0.39
▸ GABRG2 P18507 1/20 0.39
▸ GABRB3 P28472 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ GABRA3 P34903 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15254389 0.77 CYP1A2 (0.48) PDK2ALDH1A1CYP1A2CHRM2OPRM1
SCHEMBL15254386 0.77 CYP1A2 (0.48) PDK2ALDH1A1CYP1A2CHRM2OPRM1
SCHEMBL31712163 0.76 GAA (0.55) GAAALDH1A1CYP1A2CYP2C9MEN1
SCHEMBL2077117 0.76 GAA (0.55) GAAALDH1A1CYP1A2CYP2C9MEN1
SCHEMBL22201152 0.75 ACHE (0.52) ALDH1A1CYP1A2CHRM2OPRM1DDB1
SCHEMBL22190395 0.75 ACHE (0.52) ALDH1A1CYP1A2CHRM2OPRM1DDB1
SCHEMBL24753894 0.73 GAA (0.51) GAAALDH1A1CYP1A2CYP2C9MEN1
SCHEMBL13743062 0.73 GAA (0.47) GAAALDH1A1CYP1A2CHRM2TDP1
SCHEMBL2078273 0.72 GAA (0.50) GAAALDH1A1CYP1A2TDP1CYP2C9
SCHEMBL31330856 0.71 CHRM3 (0.46) GAAALDH1A1CYP1A2CHRM2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114591223-B Beta-lactamase inhibitor compounds 恩塔西斯治疗有限公司 2025-01-24 — — CN disclosed
EP-3512851-B1 BETA-LACTAMASE INHIBITOR COMPOUNDS ENTASIS THERAPEUTICS LTD (GB) 2022-07-06 — — EP disclosed
EP-3512851-B1 BETA-LACTAMASE INHIBITOR COMPOUNDS ENTASIS THERAPEUTICS LTD (GB) 2022-07-06 — — EP disclosed
CN-114591223-A Beta-lactamase inhibitor compounds 恩塔西斯治疗有限公司 2022-06-07 — — CN disclosed
CN-109715630-B Beta-lactamase inhibitor compounds 恩塔西斯治疗有限公司 2022-02-22 — — CN disclosed
US-10800778-B2 Beta-lactamase inhibitor compounds ENTASIS THERAPEUTICS LIMITED (GB) 2020-10-13 — — US disclosed
US-10800778-B2 Beta-lactamase inhibitor compounds ENTASIS THERAPEUTICS LIMITED (GB) 2020-10-13 — — US disclosed
EP-3512851-A1 BETA-LACTAMASE INHIBITOR COMPOUNDS Entasis Therapeutics Limited (GB) 2019-07-24 — — EP disclosed
US-20190202832-A1 BETA-LACTAMASE INHIBITOR COMPOUNDS ENTASIS THERAPEUTICS LIMITED (GB) 2019-07-04 — — US disclosed
US-20190202832-A1 BETA-LACTAMASE INHIBITOR COMPOUNDS ENTASIS THERAPEUTICS LIMITED (GB) 2019-07-04 — — US disclosed
WO-2018053215-A1 BETA-LACTAMASE INHIBITOR COMPOUNDS ENTASIS THERAPEUTICS LIMITED (GB) 2018-03-22 — — WO disclosed
WO-2018053215-A1 BETA-LACTAMASE INHIBITOR COMPOUNDS ENTASIS THERAPEUTICS LIMITED (GB) 2018-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190202832-A1 BETA-LACTAMASE INHIBITOR COMPOUNDS LCT, MGAM, MRPL21 GAA 7/4885PDK2 3309/4885ALDH1A1 214/4885
US-10800778-B2 Beta-lactamase inhibitor compounds LCT, MGAM, MRPL21 GAA 7/4885PDK2 3309/4885ALDH1A1 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback